Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines by Chu, Hua et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel
Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral
Cytokines
Chu, Hua; Fox, Mark; Zheng, Xia; Deng, Yanyong; Long, Yanqin; Huang, Zhihui; Du, Lijun; Xu, Fei;
Dai, Ning
DOI: https://doi.org/10.1155/2016/3230859
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136177
Published Version
Originally published at:
Chu, Hua; Fox, Mark; Zheng, Xia; Deng, Yanyong; Long, Yanqin; Huang, Zhihui; Du, Lijun; Xu, Fei;
Dai, Ning (2016). Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome:
Clinical Characteristics, Psychological Factors, and Peripheral Cytokines. Gastroenterology Research
and Practice, 2016:3230859.
DOI: https://doi.org/10.1155/2016/3230859
Research Article
Small Intestinal Bacterial Overgrowth in Patients
with Irritable Bowel Syndrome: Clinical Characteristics,
Psychological Factors, and Peripheral Cytokines
Hua Chu,1 Mark Fox,2,3 Xia Zheng,1 Yanyong Deng,1 Yanqin Long,1 Zhihui Huang,1
Lijun Du,1 Fei Xu,1 and Ning Dai1
1Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China
2Division of Gastroenterology & Hepatology, University Hospital Zu¨rich, Zu¨rich, Switzerland
3Zu¨rich Centre for Integrative Human Physiology (ZIHP), University of Zu¨rich, Zu¨rich, Switzerland
Correspondence should be addressed to Ning Dai; ndaicn@yahoo.com
Received 4 March 2016; Accepted 17 April 2016
Academic Editor: Qasim Aziz
Copyright © 2016 Hua Chu et al.This is an open access article distributed under the Creative CommonsAttribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Small intestinal bacterial overgrowth (SIBO) has been implicated in the pathogenesis of irritable bowel syndrome (IBS).
Psychosocial factors and low-grade colonic mucosal immune activation have been suggested to play important roles in the
pathophysiology of IBS. In total, 94 patients with IBS and 13 healthy volunteers underwent a 10 g lactulose hydrogen breath
test (HBT) with concurrent 99mTc scintigraphy. All participants also completed a face-to-face questionnaire survey, including
the Hospital Anxiety and Depression Scale, Life Event Stress (LES), and general information. Serum tumour necrosis factor-
𝛼, interleukin- (IL-) 6, IL-8, and IL-10 levels were measured. The 89 enrolled patients with IBS and 13 healthy controls had no
differences in baseline characteristics. The prevalence of SIBO in patients with IBS was higher than that in healthy controls (39%
versus 8%, resp.; 𝑝 = 0.026). Patients with IBS had higher anxiety, depression, and LES scores, but anxiety, depression, and LES
scores were similar between the SIBO-positive and SIBO-negative groups. Psychological disorders were not associated with SIBO
in patients with IBS. The serum IL-10 level was significantly lower in SIBO-positive than SIBO-negative patients with IBS.
1. Introduction
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder (FGID) characterised by recurrent
abdominal pain or discomfort associated with alterations in
stool frequency and/or consistency, for which there is no
apparent physical or biochemical cause to explain the symp-
toms. About 10–20% [1] of adults in western countries and
5–10% [2–4] of Asian adults are affected by IBS. It seriously
affects quality of life and consumes vast medical resources.
The pathogenesis and pathophysiology of IBS are complex
and remain incompletely understood. Visceral hypersensitiv-
ity and abnormal gastrointestinal motility are possible major
pathophysiologies, but other factors may include brain-gut
dysfunction, psychological disorders, dietary issues, gastroin-
testinal infections, and genetics.
Small intestinal bacterial overgrowth (SIBO) has received
increasing attention, and many studies have shown that the
frequency of SIBO in patients with IBS is higher than that
in a healthy population [5–8]. SIBO is a condition in which
the small bowel is colonised by colonic bacteria, resulting in
symptoms ranging frombloating and diarrhoea toweight loss
and nutritional deficiencies. However, the diagnostic tests
for SIBO remain controversial. Direct aspiration and culture
of organisms are the gold standard for diagnosing SIBO,
formally defined as the presence of >105 colony-forming
units in jejunal aspirate; however, this approach is obviously
invasive and difficult to perform, and aspirates from the
proximal jejunum lack sensitivity in all but the most severe
cases of enteric dysfunction. The lactulose hydrogen breath
test (LHBT) is the most commonly used method to diagnose
SIBO, but its accuracy has been questioned by many scholars
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2016, Article ID 3230859, 8 pages
http://dx.doi.org/10.1155/2016/3230859
2 Gastroenterology Research and Practice
because of individual variations in small intestinal transit
[9]. We published a paper confirming that LHBT alone is
not a valid test for SIBO [10]; however, LHBT combined
with scintigraphicmeasurements of the orocaecal transit time
(OCTT) provides an accurate and reproducible diagnostic
test for SIBO. In the present study, we used this method to
diagnose SIBO.
The main mechanisms of the development of SIBO are
thought to include structural changes in the gastrointestinal
tract, disordered gastric and/or small intestinal peristalsis,
and disruption of normal mucosal small intestinal defences
[11]. Abnormally low intestinal motility and immune acti-
vation may explain SIBO in a patient with IBS. Bacterial
products, such as endotoxins, can affect gut motility [12].
Gut bacteria are also important for activating an immune
response. Immune-mediated cytokines havemultiple actions,
including altered epithelial secretion, exaggerated nocicep-
tive signalling, and abnormal motility [13]. Together, these
changes may lead to IBS.
There is also considerable evidence that psychological
and social influences can affect the perception of symptoms,
healthcare-seeking behaviours, and outcomes in patients
with FGIDs, particularly those with IBS [14, 15]. Little infor-
mation is available about anxiety or depression in patients
with IBS and SIBO. However, there is a large body of work
demonstrating that patientswith IBS have low-grade immune
activation, and associations between psychological state and
stress and immune activation have been detected in mucosa
[16–19]. Results from animal experiments suggest that low-
grade gut inflammation can alter gastrointestinal tract motor
function [20] and that gut motility abnormalities can further
predispose to bacterial overgrowth.
However, the relationships among SIBO, psychologi-
cal factors, and proinflammatory and anti-inflammatory
cytokines have not been established in patients with IBS.
Thus, this study was designed to examine the clinical char-
acteristics, psychological states, and serum cytokine levels
in patients with IBS and SIBO to better understand the
pathology of IBS.
2. Materials and Methods
The study was approved by the Ethics Committee of Sir Run
Run Shaw Hospital (reference number, 20070823-2). All par-
ticipants provided written informed consent before the study.
2.1. Participants. Data from 94 consecutive patients who
met the Rome III criteria for IBS and 13 healthy volunteers
with no history of gastrointestinal symptoms were studied.
Patients had no alarm symptoms and no evidence of relevant
organic diseases on colonoscopy, routine blood tests, or
faecal microbiology. The participants were from the same
population as those used in a previous study [10].
2.2. Assessment of Psychosocial Status and General Informa-
tion. Psychological status was assessed with the Hospital
Anxiety and Depression Score (HADS), and psychosocial
stress was assessed by the Life Event Stress (LES) scale of
Miller and Rahe, asmodified and validated for use in Chinese
populations [21]. A HADS score of ≥11 was considered to
represent clinically significant anxiety or depression, with
a cut-off score of ≥8 for diagnosing borderline neurosis.
Anxiety and depression were defined as scores of ≥8 on
each respective scale for the categorical analysis.The subject’s
demographic data (age, sex, marital status, education, profes-
sion, and income range), smoking, alcohol consumption, and
medical and surgical history were recorded.
2.3. Combined LHBT and Scintigraphic Orocaecal Transit
(SOCT) Study. The subjects were instructed to avoid foods
containing incompletely absorbed carbohydrates, such as
bread, corn, pasta, and potatoes, on the evening before
the breath test and then underwent a minimum 12 h fast
to minimise basal hydrogen excretion [22]. Immediately
before the procedure, the subjects used 30mL of antiseptic
mouthwash (1.5% compound borax solution; Winguidehp,
Shanghai, China) to eliminate lactulose fermentation due
to oropharyngeal bacteria. Other extraintestinal influences
on breath hydrogen concentrations, such as cigarette smoke,
physical exercise, and hyperventilation [23], were avoided
during the test. Subjects fasted for the duration of the test.
After determining the baseline H
2
breath concentration,
all subjects underwent combined LHBT/scintigraphy. As
described previously [24], 10 g of lactulose (15mL; Dupha-
lac Solvay Pharmaceuticals B.V., Weesp, The Netherlands)
labelled with 37MBq 99mTc-diethylene triamine pentaacetic
acid (HTACo. Ltd., Beijing, China) was ingested with 100mL
of water. The subjects were placed in the supine position
with a gamma camera (Millennium VG; General Elec-
tric, Milwaukee, WI, USA) monitoring the abdomen. End-
expiratory breath samples were collected concurrently with
scintigraphic images after the meal and then every 15min
for up to 3 h using a portable analyser with a sensitivity of
±1 ppm (Micro H
2
Meter; Micro Medical Limited, Chatham,
UK). The geometric mean of the anterior and posterior
values was used for scintigraphy to correct for depth changes
(geometric mean counts = square root [anterior counts ×
posterior counts]) corrected for radioisotope decay [25]. The
scintigraphy images were reviewed independently and in a
blinded manner by two investigators to determine the arrival
of the tracer in the caecal region of interest. The OCTT was
defined as the time at which at least 5% of the administered
isotope dose had accumulated in the caecal region [9, 24].The
temporal association between increased breathH
2
and arrival
of the marker in the caecum was assessed.
2.4. Diagnostic Criteria. The diagnostic criterion for SIBO
was an initial H
2
increase involving at least two consecutive
values of ≥5 ppm above baseline, beginning at least 15min
before an increase in radioactivity (≥5% of administered
dose) in the caecal region. In previous publication [10], we
have demonstrated that combined LHBT/SOCT is a valid
method for noninvasive diagnosis of SIBO. A 5 ppm increase
in breath H
2
prior to the arrival of cecal contrast may identify
a subset of IBS patients that have good clinical outcomes
following antibiotic therapy. Figure 1 showed the results that
had been published.
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Figure 1: SIBO prevalence in IBS patients and healthy controls as
determined by six published diagnostic criteria. Only Criterion 4 for
the combined lactulose HBT/SOCT indicated a higher prevalence
of SIBO in patients than controls (which has been published).
Criterion 1: a H
2
rise of ≥20 ppm within 180min; Criterion 2: a H
2
rise of ≥20 ppm within 90min; Criterion 3: dual breath H
2
peaks, a
12 ppm increase in breathH
2
over baselinewith a decrease of≥5 ppm
before the second peak; Criterion 4: initial H
2
rise, involving at
least two consecutive values ≥5 ppm above baseline, commenced at
least 15min before an increase of radioactivity (≥5% of administered
dose) in the caecal region; Criterion 5: initial H
2
rise, involving at
least two consecutive values ≥10 ppm above baseline, commenced at
least 15min before an increase of radioactivity (≥5% of administered
dose) in the caecal region; Criterion 6: initial H
2
rise, involving at
least two consecutive values≥20 ppm above baseline, commenced at
least 15min before an increase of radioactivity (≥5% of administered
dose) in the caecal region; ∗𝑝 < 0.05.
2.5. Serum Cytokine Tests. Twelve-hour fasting venous blood
samples were drawn from patients. Whole-blood samples
(2mL)were collected in tubes containing ethylenediaminete-
traacetic acid. The samples were centrifuged immediately,
and serum was frozen at −80∘C until further use. Serum
tumour necrosis factor- (TNF-) 𝛼, interleukin- (IL-) 6, IL-
8, and IL-10 levels were quantified using enzyme-linked
immunosorbent assay kits (eBioscience, San Diego, CA,
USA) according to the manufacturer’s protocols. Optical
density was measured at a wavelength of 450 nm. Density
values were correlated linearly with the concentrations of
cytokine standards.
2.6. Statistical Analysis. All statistical analyses were per-
formed using SPSS version 19.0 for Windows software (SPSS
Inc., Chicago, IL, USA). All variables are expressed as means
± standard deviations or medians with quartiles, as appro-
priate. Student’s 𝑡-test was used to compare means, and the
Mann-Whitney𝑈 test was used as a nonparametric statistical
test. We used the 𝜒2 test for qualitative data comparisons.
Alpha values of<0.05were considered statistically significant.
3. Results
3.1. Study Population. In total, 94 patients with IBS and
13 healthy volunteers with no history of gastrointestinal
symptoms were analysed. Five patients were excluded (𝑛 = 4
hydrogen nonproducers, 𝑛 = 1 pancreatic cancer diagnosed
after study entry). The patients and healthy controls were
similar in age and sex (Table 1). Among the 89 subjects,
most of the patients with IBS had diarrhoea-predominant
IBS (IBS-D; 70.8%) or mixed type IBS (IBS-M; 23.6%); very
few had constipation-predominant IBS (IBS-C; 3.4%) or the
unsubtyped types (IBS-U; 2.2%) (Table 2).
According to the diagnostic criterion, 35/89 (39%)
patients and 1/13 (8%) were diagnosed as SIBO-positive,
whereas the others were SIBO-negative. The prevalence of
SIBO in patients with IBS was higher than that in healthy
controls (𝑝 = 0.026), as we showed previously. The demo-
graphic and clinical characteristics were similar in patients
with IBS with and without SIBO, except marital status
(Table 3). Figure 1 had showed the reason that we selected
these criteria and the paper had been published in the Journal
of Neurogastroenterology and Motility [10].
3.2. Psychological State Reflected byHADSandLife Event Stress
(LES). Patients with IBS had higher anxiety, depression, and
LES scores than did healthy controls (Table 1). However, the
SIBO-positive and SIBO-negative patients exhibited similar
scores for anxiety (5.37 ± 3.61 versus 5.04 ± 2.85, resp.; 𝑝 =
0.628) and depression (5.86 ± 3.90 versus 5.30 ± 2.87, resp.;
𝑝 = 0.437) (Table 4). Similarly, LES scores of patients with
IBS and SIBO were comparable to those of patients without
SIBO.
3.3. Serum Cytokines. The IL-10 level was significantly lower
in SIBO-positive than SIBO-negative patients with IBS
(mean, 12.92 pg/mL [range, 11.40–14.85 pg/mL], versusmean,
14.03 pg/mL [range, 12.66–16.33 pg/mL], resp.; 𝑝 = 0.026).
No differences were observed in TNF-𝛼, IL-6, or IL-8 levels
between the groups (Table 5).
4. Discussion
SIBOhas been suggested to play a role in the pathophysiology
of IBS, but the reported prevalence of SIBO in patients
with IBS varies widely depending on the geographical origin
of the study population, methods for detection, and crite-
ria for diagnosing SIBO. Our results demonstrate that the
prevalence of SIBO was higher in patients with IBS than in
healthy controls, as we showed previously [10].Thediagnostic
criterion for SIBO by combining LHBT with scintigraphic
measurement is certificated in our previous study [10]. We
found no relationship between SIBO and age, sex, BMI, or
alcohol consumption. Many studies have demonstrated that
older age and female sex are predictors of SIBO [26–29].More
females thanmales are diagnosed with IBS, and SIBO is more
common in older individuals, likely due to reduced intestinal
motility with advancing age [29]. However, consistent with
Rana’s report, we found no relationship between SIBO and
old age or sex [30]. In a retrospective review, Gabbard et
al. [31] reported that moderate alcohol consumption is a
strong risk factor for SIBO. Previous studies [32, 33] have
demonstrated that alcoholics have higher rates of SIBO. The
main mechanisms for the development of SIBO include
structural changes in the gastrointestinal tract, disordered
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Table 1: Baseline demographic factors of the patients and controls.
Patients with IBS Healthy controls p value
(𝑛 = 89) (𝑛 = 13)
Age in years, mean ± SD 45.7 ± 12.9 43.3 ± 8.6 0.595
Sex, male/female 47/42 9/4 0.266
BMI, kg/m2 22.1 ± 5.8 24.5 ± 2.9 0.245
Anxiety, mean ± SD 5.17 ± 3.16 2.77 ± 1.64 0.009
Depression, mean ± SD 5.52 ± 3.30 3.54 ± 2.50 0.041
LES 40.0 (11.0–75.0) 8.0 (0.0–35.0) <0.001
Table 2: Baseline comparison of the small intestinal bacterial overgrowth- (SIBO-) positive and negative patients.
SIBO (+) (𝑛 = 35) SIBO (−) (𝑛 = 54) p value
Age in years, mean ± SD 43.5 ± 12.5 47.2 ± 13.1 0.187
Sex, male/female 21/14 26/28 0.274
BMI, kg/m2 23.2 ± 7.7 21.4 ± 4.0 0.139
IBS-D 28 35 0.124
IBS-C 1 2 1.000
IBS-M 6 15 0.248
IBS-U 0 2 0.517
Table 3: General characteristics of the small intestinal bacterial overgrowth- (SIBO-) positive and negative patients with irritable bowel
syndrome.
Variables Levels SIBO (+) (𝑛 = 35) SIBO (−) (𝑛 = 54) p value
Age, years Mean ± SD 43.5 ± 12.5 47.2 ± 13.1 0.187
Sex, n (%) Male 21 (60.0%) 26 (48.1%)
Female 14 (40.0%) 28 (51.9%) 0.274
BMI, kg/m2 Mean ± SD 23.2 ± 7.7 21.4 ± 4.0 0.139
Marital status, n (%) Married 29 (82.9%) 52 (96.3%)
Single 6 (17.1%) 2 (3.7%) 0.030
Education, n (%)
≤Primary 8 (22.9%) 11 (20.4%)
Middle school 10 (28.6%) 19 (35.2%)
High school 9 (25.7%) 15 (27.8%) 0.848
≥College 8 (22.9%) 9 (16.7%)
Average family income, n (%)
<1000 3 (8.6%) 2 (3.7%)
≥1000 18 (51.4%) 35 (64.8%) 0.470
≥5000 10 (28.6%) 10 (18.5%)
≥10000 4 (11.4%) 7 (13.0%)
Job, n (%)
Office work 4 (11.4%) 6 (11.1%)
Physical work 22 (62.9%) 36 (66.7%) 0.924
Housework 9 (25.7%) 12 (22.2%)
Cigarette smoking, n (%)
Never 24 (68.6%) 44 (81.5%)
≥1 7 (20.0%) 7 (13.0%) 0.520
≥10 2 (5.7%) 1 (1.9%)
≥20 2 (5.7%) 2 (3.7%)
Alcohol drinking, n (%)
Never 16 (45.7%) 25 (46.3%)
Sometimes 17 (48.6%) 26 (26.1%) 0.840
Often 0 (0.0%) 1 (1.9%)
Always 2 (5.7%) 2 (3.7%)
Medical history, n (%) No 27 (77.1%) 39 (72.2%) 0.604
Yes 8 (22.9%) 15 (27.8%)
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Table 4: Hospital anxiety and depression scale and life event stress scores in patients with irritable bowel syndrome with and without small
intestinal bacterial overgrowth (SIBO).
SIBO (+) (𝑛 = 35) SIBO (−) (𝑛 = 54) Healthy controls (𝑛 = 13)
Anxiety (mean ± SD) 5.37 ± 3.61∗ 5.04 ± 2.85∗ 2.77 ± 1.64
Depression (mean ± SD) 5.86 ± 3.90∗ 5.30 ± 2.87∗ 3.54 ± 2.50
Life event stress 42.0 (11.0–99.0)∗ 39.50 (0.0–69.25)∗ 8.0 (0.0–35.0)
∗p < 0.05 compared with healthy controls.
Table 5: Serum cytokine levels in small intestinal bacterial overgrowth- (SIBO-) positive and negative patients (pg/mL).
SIBO (+) (𝑛 = 35) SIBO (–) (𝑛 = 54) p value
TNF-𝛼 9.77 (5.16–15.24) 9.41 (6.09–13.49) 0.938
IL-6 6.84 (6.69–7.07) 6.76 (6.65–7.13) 0.678
IL-8 17.67 (5.30–36.19) 12.49 (5.94–48.96) 0.911
IL-10 12.92 (11.40–14.85) 14.03 (12.66–16.33) 0.026
gastric and/or small intestinal peristalsis, and disruption of
the normal mucosal defences of the small intestine [11].
However, we found no association between SIBO and alcohol
consumption in the present study.
Previous studies [14, 34] have confirmed that anxiety and
depression are more common in patients with FGIDs than
in the healthy population, particularly in patients with IBS,
as confirmed here. Anxiety, depression, and life event stress
were more prevalent in patients with IBS than in healthy
controls. However, whether patients IBS and SIBO have
more severe psychological disorders is unknown. Our study
showed similar levels of anxiety and depression, including
life event stress experience. A possible explanation may be
that the symptoms of SIBO are similar to those of IBS, such
as bloating, diarrhoea, abdominal pain, and malabsorption.
Thus, SIBO does not further aggravate the psychological
status in patients with IBS. This finding was consistent with
Grover et al. [35], who reported no difference in psychological
distress between SIBO-positive and SIBO-negative patients
with IBS. Thus, it seems unlikely that psychological distress
mediates the association between SIBO and bowel symptoms.
However, one study found an increase in the number of
positive breath tests in patients with fibromyalgia, suggesting
an association between psychological distress factors, such as
somatisation, and SIBO [36]. Another study demonstrated
that state anxiety is related to SIBO [37]. No study has
investigated psychological distress as a moderating variable
in patients with SIBO.
Many studies have demonstrated that some patients with
IBS display persistent signs of low-grade mucosal inflamma-
tion, with activated T lymphocytes, B lymphocytes, and mast
cells and increased expression of proinflammatory cytokines
such as TNF-𝛼 and IL-6 [38–41]. We found that serum IL-
10 level was significantly lower in SIBO-positive than SIBO-
negative patients with IBS, whereas the TNF-𝛼, IL-6, and
IL-8 levels were similar in both groups. IL-10 is an anti-
inflammatory cytokine produced by T cells, B cells, and
monocytes and inhibits synthesis of other cytokines. Thus,
a decrease in the IL-10 level could predispose a patient to
increased mucosal cytokine production during infections
or other mucosal insults [42]. Intestinal inflammation and
activation of the immune response can cause a cytokine
imbalance. Experimental data suggest that inflammation,
even if mild, can lead to persistent changes in gastrointestinal
nerve and smooth muscle function, resulting in colonic
dysmotility, hypersensitivity, and dysfunction [43]. It has
also been reported from animal experiments that low-grade
gut inflammation alters gastrointestinal tract motor function
[20, 44]. Gut motility abnormalities can further predispose
to bacterial overgrowth. Many studies have reported that
a delayed OCTT is associated with SIBO in patients with
diabetes mellitus, ulcerative colitis, and several other diseases
[45–47].
This is the first report of lower peripheral serum IL-10
levels in SIBO-positive than SIBO-negative patients with IBS.
Many studies have reported that IL-10 expression is lower in
patients with IBS than in healthy controls [48–50], but studies
on changes in peripheral cytokines in patients with IBS with
or without SIBO are rare. Riordan et al. [51] investigated
patients with SIBO by culturing proximal small intesti-
nal luminal secretions and measuring luminal interferon-
𝛾, IL-6, and TNF-𝛼 concentrations. They found increased
mucosal production of IL-6 in SIBO-positive subjects. The
subjects they recruited were patients with pure SIBO, not
patients with IBS, and cytokines were assessed from intestinal
luminal secretions, which may reflect cytokine levels more
accurately than peripheral blood. In animal experiments,
German et al. [52] examined the role of cytokines in the
immunopathogenesis of SIBO in German shepherd dogs.
Duodenal mucosal biopsies were taken, and mRNA expres-
sion of various cytokines was determined by semiquantitative
reverse transcriptase polymerase chain reaction. IL-2, IL-5,
IL-12p40, TNF-𝛼, and transforming growth factor-𝛽1 mRNA
levels in SIBO-positive dogs were significantly greater than
those in SIBO-negative dogs.
This study had some limitations. First, relatively small
numbers of patients and controls were recruited. Second, we
did not test cytokine profiles in the healthy controls.Third, we
assessed cytokine profiles in peripheral blood rather than in
mucosa or tissue. Measuring cytokine levels in the intestine
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or colon may be more appropriate. Future studies will assess
activation of the immune response in the mucosa of SIBO-
positive patients with IBS and healthy controls.
In summary, we conclude that SIBO is unlikely to be
associated with older age, sex, alcohol consumption, or
psychological disorders. Our results suggest that lower serum
production of IL-10 occurs in SIBO-positive than SIBO-
negative patients with IBS. Future studies will assess low-
grade inflammation and immune activation status by deter-
mining the imbalance of cytokines and immune cell changes
from intestinal biopsies in patients with IBS and SIBO. Such
data will be valuable to develop a better understanding of the
role of SIBO in the pathogenesis of IBS.
Additional Points
Small intestinal bacterial overgrowth (SIBO) has been impli-
cated in the pathogenesis of irritable bowel syndrome (IBS),
although the issue remains controversial. Psychosocial factors
and low-grade colonicmucosal immune activation have been
suggested to play important roles in the pathophysiology of
IBS. Our results suggest that lower serum production of IL-
10 occurs in SIBO-positive than SIBO-negative patients with
IBS.
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